Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19128878 | 0.85 | RHOA (0.43) | ALDH1A1LMNAMAPT | |
| SCHEMBL27988389 | 0.82 | KDM4E (0.51) | GPR119BACE1KDM4EPKM | |
| SCHEMBL20364206 | 0.81 | MAPT (0.43) | ALDH1A1LMNAMAPT | |
| SCHEMBL19127895 | 0.79 | ALDH1A1 (0.47) | ALDH1A1LMNAMAPTGPR119BACE1 | |
| SCHEMBL25239760 | 0.79 | ALDH1A1 (0.48) | ALDH1A1LMNAMAPTGPR119BACE1 | |
| SCHEMBL3507796 | 0.79 | ALDH1A1 (0.49) | ALDH1A1LMNAMAPTGPR119BACE1 | |
| SCHEMBL26151149 | 0.79 | FPR2 (0.47) | ALDH1A1GPR119BACE1KDM4EPKM | |
| SCHEMBL17458879 | 0.78 | GPR119 (0.44) | ALDH1A1LMNAMAPTGPR119BACE1 | |
| SCHEMBL16227930 | 0.78 | FPR2 (0.41) | ALDH1A1LMNAGPR119BACE1KDM4E | |
| SCHEMBL3352407 | 0.76 | MAPT (0.50) | ALDH1A1LMNAMAPTGPR119KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981926-B2 | Substituted thiohydantoin derivatives as androgen receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-20 | — | — | US | disclosed |
| US-20200109150-A1 | Substituted Thiohydantoin Derivatives As Androgen Receptor Antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-09 | — | — | US | disclosed |
| EP-3402791-A1 | SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2018-11-21 | — | — | EP | disclosed |
| US-20180298021-A1 | Substituted Thiohydantoin Derivatives As Androgen Receptor Antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2018-10-18 | — | — | US | disclosed |
| US-10000502-B2 | Substituted thiohydantoin derivatives as androgen receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-19 | — | — | US | disclosed |
| US-20170233401-A1 | SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-17 | — | — | US | disclosed |
| US-20170233401-A1 | SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-17 | — | — | US | disclosed |
| US-20170233401-A1 | SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-17 | — | — | US | disclosed |
| WO-2017123542-A1 | SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-20 | — | — | WO | disclosed |
| WO-2017123542-A1 | SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981926-B2 | Substituted thiohydantoin derivatives as androgen receptor antagonists | AR, SHBG, NR5A1 | ALDH1A1 350/4885LMNA 4294/4885MAPT 3804/4885 |
| US-20180298021-A1 | Substituted Thiohydantoin Derivatives As Androgen Receptor Antagonists | AR, SHBG, NR5A1 | ALDH1A1 350/4885LMNA 4294/4885MAPT 3804/4885 |
| US-20170233401-A1 | SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | AR, SHBG, NR5A1 | ALDH1A1 350/4885LMNA 4294/4885MAPT 3804/4885 |
| US-10000502-B2 | Substituted thiohydantoin derivatives as androgen receptor antagonists | AR, SHBG, NR5A1 | ALDH1A1 350/4885LMNA 4294/4885MAPT 3804/4885 |
| US-20200109150-A1 | Substituted Thiohydantoin Derivatives As Androgen Receptor Antagonists | AR, SHBG, NR5A1 | ALDH1A1 350/4885LMNA 4294/4885MAPT 3804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.